Company Overview - Angli康 is a pharmaceutical company based in Shengzhou, Zhejiang Province, established on December 30, 2001, and listed on October 23, 2018. The company focuses on the research, production, and sales of chemical raw materials and formulations [1][2]. Financial Performance - For the period from January to September 2025, Angli康 reported a revenue of 1.055 billion yuan, a year-on-year decrease of 5.92%. However, the net profit attributable to shareholders increased by 55.59% to 77.6899 million yuan [2]. - The company has distributed a total of 360 million yuan in dividends since its A-share listing, with 128 million yuan distributed over the past three years [3]. Stock Performance - As of November 26, Angli康's stock price increased by 2.04% to 40.60 yuan per share, with a total market capitalization of 8.19 billion yuan. The stock has risen by 213.25% year-to-date, although it has seen a decline of 0.55% over the last five trading days [1]. - The stock has appeared on the "龙虎榜" (a trading board for stocks with significant trading activity) 15 times this year, with the most recent appearance on October 21, where it recorded a net buy of 15.2289 million yuan [1]. Shareholder Structure - As of September 30, 2025, Angli康 had 28,500 shareholders, an increase of 54.58% from the previous period. The average number of circulating shares per shareholder decreased by 35.31% to 6,493 shares [2]. - Notable institutional shareholders include 广发医疗保健股票A, 中欧医疗健康混合A, and several new entrants such as 汇添富创新医药混合A and 长城医药产业精选混合发起式A [3]. Industry Classification - Angli康 operates within the pharmaceutical and biotechnology sector, specifically in the chemical pharmaceutical and chemical formulation sub-industry. The company is associated with various concepts, including ursodeoxycholic acid, Helicobacter pylori, pet economy, hypertension prevention, and vitamins [2].

Group 1 - *ST Dongtong's stock is suspended and may face delisting [1] - Fusenmei's Deputy General Manager and Board Secretary Zhang Fengshu is under investigation and has been detained [1] - Two Mian Zhen plans to invest 68.85 million yuan in the expansion of its traditional Chinese medicine oral care product production base [1] Group 2 - Samsung Medical is expected to win a 107 million yuan bid for a State Grid procurement project [1] - Suzhou High-tech plans to sell 47% of its medical device subsidiary for 604 million yuan [1] - Hengmingda has repurchased 2% of its shares [1] Group 3 - Wanrun Co.'s actual controller plans to increase holdings by 365 million to 730 million yuan [1][2] - Shenling Environment intends to issue convertible bonds to raise up to 1 billion yuan for a liquid cooling manufacturing project [1] - Anglikang plans to raise 1.16 billion yuan through a private placement for innovative drug research and industrialization [1][2]

Core Viewpoint - The company, Anglicon, plans to raise 1.16 billion yuan through a private placement of A-shares to fund innovative drug research and industrialization projects [2] Group 1: Fundraising and Purpose - The company aims to expand its funding sources through the issuance of A-shares [2] - The raised funds will accelerate the research and development process of innovative drugs [2] - The initiative is expected to enhance the company's new product pipeline and create new profit growth points [2] Group 2: Strategic Benefits - Successful implementation of the project will strengthen the company's research and innovation capabilities [2] - The move is anticipated to improve the company's overall strength and market positioning in the innovative drug sector [2]

Core Viewpoint - The company, Anglikang (002940), announced plans to issue A-shares to specific investors to raise 1.16 billion yuan for innovative drug research and industrialization projects [1] Group 1 - The company aims to raise funds amounting to 1.16 billion yuan through a targeted A-share issuance [1] - The raised funds will be allocated specifically for innovative drug development and industrialization projects [1]

Core Viewpoint - The company, Anglikang (002940.SZ), has announced a plan to issue A-shares to specific investors in 2025, aiming to raise 1.16 billion yuan for innovative drug research and industrialization projects [1] Group 1 - The company plans to issue shares to no more than 35 specific investors [1] - The issuance price will be no less than 80% of the average stock price over the 20 trading days prior to the pricing benchmark [1] - The total number of shares issued will not exceed 30% of the company's total share capital before the issuance, amounting to a maximum of 60.5185 million shares [1] Group 2 - The total funds to be raised through this issuance are set at 1.16 billion yuan [1] - The funds will be allocated specifically for "innovative drug research and industrialization projects" [1]

每经AI快讯，昂利康（SZ 002940，收盘价：39.79元）11月25日晚间发布公告称，本次向特定对象发行 股票相关事项已经公司第四届董事会第十五次会议审议通过。本次发行采用向特定对象发行股票的方 式，发行对象不超过35名（含35名）。本次向特定对象发行股票的数量按照募集资金总额除以发行价格 确定，且不超过本次发行前公司总股本的30%，即不超过约6051.85万股（含本数）。发行价格不低于 定价基准日前二十个交易日公司股票均价的80%。 本次募集资金扣除发行费用后，拟用于以下项目：创新药研发及产业化项目，总投资约11.96亿元，拟 投入募集资金11.6亿元；创新药研发项目，总投资约6.77亿元，拟投入募集资金6.7亿元；创新药产业化 项目，总投资约5.18亿元，拟投入募集资金4.9亿元。 每经头条（nbdtoutiao）——688496，被证监会立案！刚上市业绩就变脸，亏损超1亿元；核心产品受重 创：第一大客户"自产自用"，减少采购 （记者 胡玲） 2025年1至6月份，昂利康的营业收入构成为：医药制造业占比100.0%。 截至发稿，昂利康市值为80亿元。 ...

智通财经APP讯，昂利康(002940.SZ)披露2025年度向特定对象发行A股股票预案，公司拟向不超过35名 (含)特定对象发行股票，发行价格不低于定价基准日前二十个交易日公司股票均价的80%，数量按照募 集资金总额除以发行价格确定，且不超过本次发行前公司总股本的30%，即不超过6051.85万股(含本 数)。拟募集资金11.6亿元，用于"创新药研发及产业化项目"。 ...

证券代码：002940 证券简称：昂利康 浙江昂利康制药股份有限公司 Zhejiang AngLiKang Pharmaceutical CO.,LTD. （嵊州市嵊州大道北 1000 号） 2025 年度向特定对象发行 A 股股票预案 二〇二五年十一月 浙江昂利康制药股份有限公司 2025年度向特定对象发行A股股票预案 上市公司声明 1、本公司及董事会全体成员保证本预案内容真实、准确、完整，不存在虚 假记载、误导性陈述或重大遗漏，按照诚信原则履行承诺，并承担相应的法律责 任。 2、本预案按照《中华人民共和国公司法》《中华人民共和国证券法》《上 市公司证券发行注册管理办法》等法规及规范性文件的要求编制。 3、本次向特定对象发行股票完成后，公司经营与收益的变化由公司自行负 责；因本次向特定对象发行股票引致的投资风险，由投资者自行负责。 4、本预案是公司董事会对本次向特定对象发行股票的说明，任何与之不一 致的声明均属不实陈述。 5、投资者如有任何疑问，应咨询自己的股票经纪人、律师、专业会计师或 其他专业顾问。 6、本预案所述事项并不代表审批机构对于本次向特定对象发行股票相关事 项的实质性判断、确认、批准。 本预案 ...

证券代码：002940 证券简称：昂利康 公告编号：2025-092 特此公告。 浙江昂利康制药股份有限公司 董 事 会 浙江昂利康制药股份有限公司 关于 2025 年度向特定对象发行 A 股股票预案披露的 提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 浙江昂利康制药股份有限公司（以下简称"公司"或"本公司"）于 2025 年 11 月 24 日召开第四届董事会第十五次会议，审议通过了关于公司 2025 年度 向特定对象发行 A 股股票的相关议案。具体内容详见公司于 2025 年 11 月 26 日 在《证券时报》及巨潮资讯网（www.cninfo.com.cn）上刊载的《浙江昂利康制药 股份有限公司 2025 年度向特定对象发行 A 股股票预案》（以下简称"预案"）及 相关文件，敬请广大投资者注意查阅。 公司本次向特定对象发行 A 股股票预案的披露事项不代表审批机关对于本 次向特定对象发行 A 股股票相关事项的实质性判断、确认、批准或予以注册， 预案所述本次发行股票相关事项的生效和完成尚须获得公司股东会审议通过、深 圳证券交易所审核通过并经中国 ...

证券代码：002940 证券简称：昂利康 浙江昂利康制药股份有限公司 Zhejiang AngLiKang Pharmaceutical CO.,LTD. （嵊州市嵊州大道北 1000 号） 释 义 在本报告中，除非另有说明，以下词汇具有如下含义： | 发行人/本公司/公司/ | 指 | 浙江昂利康制药股份有限公司 | | --- | --- | --- | | 昂利康 | | | | 董事会 | 指 | 浙江昂利康制药股份有限公司董事会 | | 股东会 | 指 | 浙江昂利康制药股份有限公司股东会 | | 本报告 | 指 | 浙江昂利康制药股份有限公司 2025 年度向特定对象发行 A 股股 | | | | 票方案的论证分析报告 | | 本次发行、本次发行 A 股股票、本次向特 | 指 | 浙江昂利康制药股份有限公司本次向特定对象发行 A 股股票的 | | | | 行为 | | 定对象发行 A 股股票 | | | | 中国证监会 | 指 | 中国证券监督管理委员会 | | 深交所 | 指 | 深圳证券交易所 | | 《公司章程》 | 指 | 《浙江昂利康制药股份有限公司章程》 | | 元、万元 | 指 | ...